JP Morgan Raises Danaher (DHR) Price Target to $270
Key Points
- JP Morgan reiterated its Overweight rating on Danaher Corporation on October 22, 2026, while raising its price target from $250.00 to $270.00.
- JP Morgan's $270 price target implies 15.75% upside from Danaher Corporation's ($DHR) current $233.27 share price.
- Capital International Investors held 15,504,420 shares worth about $3.56 billion after growing its position by 1,489,759 shares.
- Danaher shares recently traded around $233.27, up 1.6% from their October 22, 2026 close of $229.54.
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
On October 22, 2026, JP Morgan reaffirmed its Overweight rating on Danaher Corporation (NYSE:DHR) while lifting its price target from $250.00 to $270.00. The research note arrived alongside updates from several other major Wall Street firms covering the healthcare equipment and diagnostics provider. Danaher closed at $229.54 on the day of the announcement.
DHR
Danaher Corporation
JP Morgan's Call on Danaher
JP Morgan kept its Overweight rating on the stock while boosting its target by $20.00 to $270.00. The firm's forward-looking assessment follows steady operational performance across Danaher's core segments.
Other Institutional Activity in Danaher
Capital International Investors grew its holdings by 1,489,759 shares, ending with 15,504,420 shares worth about $3,558,962,060.00.
Danaher Corporation Stock Up 4.0%
Danaher shares recently traded around $233.27 as of October 22, 2026, up about 1.6% from their event-day close of $229.54. The stock trades above both its 50-day moving average of $215.12 and its 200-day moving average of $201.26. The shares sit below their 52-week high of $242.80.
$DHR price target
Danaher Corporation daily closes and this analyst's $270 target. Not advice.
Recent Earnings
Danaher reported $25.11 billion in trailing twelve month revenue alongside earnings of $6.04 per share. The company generated a net profit margin of 15.9% and a return on equity of 7.6%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend of $1.60 per share, giving the stock a dividend yield of 0.71%. The payout ratio stands at 25.7%.
Insider Buying and Selling at Danaher Corporation
Director Alan G. Spoon sold 1,358 shares on May 1, 2026, at an average price of $174.67 for a total value of $237,207.00. Later, Chief Executive Officer Rainer M. Blair disposed of 58,255 shares on August 21, 2026, valued at $12,736,095.00.
Analysts Set New Price Targets
On October 22, 2026, Barclays maintained its Overweight rating and lifted its price target from $255.00 to $260.00. On the same day, TD Cowen maintained a Buy rating while raising its target from $255.00 to $270.00. Stifel kept a Buy rating and increased its target from $220.00 to $260.00, while Baird maintained an Outperform rating and lifted its target from $246.00 to $254.00. Consensus analyst data shows a strong buy recommendation with a mean price target of $247.18 across 22 analyst opinions.
About Danaher
Danaher Corporation builds and supports professional, medical, industrial, and research products globally. The Washington, D.C.-based enterprise operates through biotechnology, diagnostics, and life sciences divisions, providing vital tools and consumables for laboratory research and clinical testing.
Bottom Line
Wall Street firms remain mostly positive on the stock following the latest round of target adjustments. Investors will watch for upcoming earnings reports and filing updates to track margin stability and segment growth across the company's healthcare portfolio.
Related Filing Alerts
Source: JP Morgan's rating change on $DHR (Oct 22, 2026). Written by software, not financial advice. How we make alerts